Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)

#904

Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.

Aim(s): To determine the role of Met on RFS in NET patients (pts).

Materials and methods: A retrospective analysis was conducted comparing NET pts with recent diagnosis (< 1 yr) of diabetes mellitus, with HbA1c≤7%, treated with Met (group A) to non-diabetic NET pts without Met (group B) with comparable clinical and pathological characteristics. RFS was evaluated by Kaplan-Meier analysis

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Marciello F

Authors: Marciello F, Del Prete M, Marotta V, Ramundo V, Buonomano P,

Keywords: prognosis, metformin, RFS, survival,

To read the full abstract, please log into your ENETS Member account.